Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aveeno Eczema Therapy Moisturizing Cream is a topical over-the-counter emollient developed by Aveeno (a brand of Johnson & Johnson/Kenvue) specifically for the management of atopic dermatitis (eczema). Its primary active ingredient is 1% colloidal oatmeal, which acts as a skin protectant to relieve minor skin irritation and itching. The formulation also includes ceramides (specifically Ceramide NP) to help strengthen the skin's natural moisture barrier and prevent the recurrence of extra-dry skin. Clinical studies have demonstrated its ability to improve skin hydration (capacitance) and support barrier function in patients with mild to moderate atopic dermatitis, often compared to other common moisturizers like Cetaphil and CeraVe.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aveeno Eczema Therapy Moisturizing Cream.